A cura di Simona Lucchesi. UOSD Farmacologia Clinica. AOU “G. Martino” di Messina
|
Farmaco |
Principio attivo |
|
Teofillina (1-4) |
Rischio di tossicità da teofillina (nausea, vomito, palpitazioni e crisi convulsive) |
Bibliografia
- Monostory K, Vereczkey L. Interaction of theophylline and ipriflavone at the cytochrome P450 level. Eur J Drug Metab Pharmacokin 1995; 20: 43-47.
- Monostory K, Vereczkey L: The effect of ipriflavone and its main metabolites on theophylline biotransformation. Eur J Drug Metab Pharmacokin 1996; 21: 61-66.
- Monostory K, et al. Ipriflavone as an inhibitor of human cytochrome P450 enzymes. Br J Pharmacol 1998; 123: 605-610.
- Takahashi J, et al. Elevation of serum theophylline levels by ipriflavone in a patient with chronic obstructive pulmonary disease. Eur J Clin Pharmacol 1992; 43: 207-208.